AR036183A1 - 1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion y su uso para la preparacion de un conjugado con una biomolecula - Google Patents

1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion y su uso para la preparacion de un conjugado con una biomolecula

Info

Publication number
AR036183A1
AR036183A1 ARP020102719A ARP020102719A AR036183A1 AR 036183 A1 AR036183 A1 AR 036183A1 AR P020102719 A ARP020102719 A AR P020102719A AR P020102719 A ARP020102719 A AR P020102719A AR 036183 A1 AR036183 A1 AR 036183A1
Authority
AR
Argentina
Prior art keywords
groups
group
atoms
radical
optionally
Prior art date
Application number
ARP020102719A
Other languages
English (en)
Inventor
Platzek Johannes Dr
Schmitt-Willich Heribert Dr
Michl Guenther Dr
Frenzel Thomas Dr
Suelzle Detlev Dr
Bauer Hans Dr
Raduechel Bernd Dr
Weinmann Hanns-Joachim Dr
Schirmer Heiko Dr
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR036183A1 publication Critical patent/AR036183A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen 1,4,7,10-tetraazaciclododecanos, de fórmula (1), donde Z representa un átomo de hidrógeno o al menos dos Z representan un equivalente de un ión metálico; B representa un átomo de hidrógeno o un radical alquilo C1-4; R representa un átomo de hidrógeno o un radical alquilo C1-10 o arilo lineal, ramificado o cíclico, saturado o insaturado que está sustituido opcionalmente por un grupo carboxilo, -SO3H ó -PO3H2, y donde la cadena de alquilo del radical alquilo C1-10 contiene opcionalmente un grupo arilo y/o 1-2 átomos de oxígeno, con la condición de que los radicales B y R no representen al mismo tiempo átomos de oxígeno; A representa una cadena de hidrocarburos C1-30 lineal o ramificada, saturada o insaturada, que contiene opcionalmente 1-5 átomos de oxígeno, 1-5 átomos de nitrógeno y/o 1-5 radicales -NR', donde R' está definido como R, pero que puede seleccionarse de modo independiente, que está opcionalmente sustituido con 1-3 grupos carboxilo, 1-3 -SO3H, 1-3 -PO3H2 y/o 1-3 átomos de halógeno, donde están presentes opcionalmente 1-3 átomos de carbono como grupos carbonilo, donde la cadena o una parte de la cadena puede estar dispuesta en forma de anillo, y que está conformada de modo tal que X está enlazado al menos a través de 3 átomos con el átomo de nitrógeno al que está unido A; X representa un grupo que puede reaccionar con una biomolécula, y sus sales, con la condición de que, (a) cuando B es un átomo de hidrógeno y R es -CH2CH2CO2H, A-X juntos no son -CH(CO2H)CH2CH2CO2H; (b) cuando B es un átomo de hidrógeno y R es un radical metilo o etilo que eventualmente está sustituido por un grupo carboxilo, A no representa el radical -CH(R4)-CO-NR2-U6, donde R2 es un átomo de hidrógeno o un radical metilo o etilo que eventualmente está sustituido por un grupo carboxilo; R4 es una cadena alquilo C1-30 lineal o ramificada, saturada o insaturada que eventualmente puede estar interrumpida por 1-10 átomos de oxígeno, un grupo fenileno, un grupo fenilenoxi o eventualmente sustituida por 1-5 grupos hidroxi, 1-3 grupos carboxi, 1 grupo fenilo y U6 es un grupo alquileno C1-20 lineal o ramificado, saturado o insaturado que contiene eventualmente 1-5 grupos imino, 1-3 grupos fenileno, 1-3 grupos fenilenoxi, 1-3 grupos fenilenimino, 1-5 grupos amida, 1-2 grupos hidracida, 1-5 grupos carbonilo, 1-5 grupos etilenoxi, 1 grupo urea, un grupo tiourea, 1-2 grupos carboxialquilimino, 1-2 grupos éster; 1-10 átomos de oxígeno, 1-5 átomos de azufre y/o 1-5 átomos de nitrógeno y/o eventualmente sustituido por 1-5 grupos hidroxi, 1-2 grupos mercapto, 1-5 grupos oxo, 1-5 grupos tioxo, 1-3 grupos carboxi, 1-5 grupos carboxialquilo, 1-5 grupos éster, y/o 1-3 grupos amino, donde los grupos fenileno eventualmente contenidos pueden estar sustituidos por 1-2 grupos carboxi, 1-2 grupos sulfo o 1-2 grupos hidroxi, y (c) cuando B es un hidrógeno y R es un radical alquilo C1-4, A no es el radical -CHR3-C(O)-NH-(CH2)1-6-NH-D- donde R3 es un átomo de hidrógeno o un radical alquilo C1-4, D es un grupo alquileno C1-4, de cadena lineal o ramificada, saturado o insaturado, que opcionalmente puede estar interrumpido o sustituido por un grupo carbonilo y D está unido a X. Procedimiento para obtener los compuestos de la fórmula (1) y uso de estos últimos para obtener un conjugado con una biomolécula. Estos conjugados son aptos como medios de contraste en el diagnóstico por RMN y radiodiagnóstico y como sustancia radioterapéutica. Con los ligandos especiales de macrociclo 1,4,7,10-tetraazaciclododecano se logra una elevada relajación y se posibilita un ajuste fino de la relajación.
ARP020102719A 2001-07-20 2002-07-19 1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion y su uso para la preparacion de un conjugado con una biomolecula AR036183A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10135356A DE10135356C1 (de) 2001-07-20 2001-07-20 Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen

Publications (1)

Publication Number Publication Date
AR036183A1 true AR036183A1 (es) 2004-08-18

Family

ID=7692471

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102719A AR036183A1 (es) 2001-07-20 2002-07-19 1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion y su uso para la preparacion de un conjugado con una biomolecula

Country Status (19)

Country Link
US (2) US7164016B2 (es)
EP (1) EP1409024B1 (es)
JP (1) JP2005504745A (es)
KR (1) KR20040030826A (es)
CN (1) CN1533286A (es)
AR (1) AR036183A1 (es)
AT (1) ATE403442T1 (es)
AU (1) AU2002321236B2 (es)
BR (1) BR0211273A (es)
CA (1) CA2453106A1 (es)
DE (2) DE10135356C1 (es)
IL (1) IL159290A0 (es)
MX (1) MXPA04000401A (es)
NO (1) NO20040238L (es)
PE (1) PE20030322A1 (es)
PL (1) PL366426A1 (es)
RU (1) RU2305096C2 (es)
UY (1) UY27390A1 (es)
WO (1) WO2003009874A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
DK1286704T3 (da) 2000-06-02 2014-09-22 Univ Texas Ethylendicystein (EC)-glucose analoge konjugater
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10325752A1 (de) * 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
DE602006008604D1 (de) 2005-04-26 2009-10-01 Koninkl Philips Electronics Nv Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex
FI20055712A0 (fi) * 2005-12-29 2005-12-29 Wallac Oy Makrosykliset oligonukleotiidien leimausreagenssit ja niistä johdetut konjugaatit
WO2007120153A1 (en) * 2006-04-19 2007-10-25 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US10556873B2 (en) 2008-02-22 2020-02-11 Illinois Institute Of Technology Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
WO2010011367A2 (en) * 2008-02-22 2010-01-28 Illinois Institute Of Technology Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
KR101253100B1 (ko) * 2010-02-16 2013-04-10 경북대학교 산학협력단 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
KR101236142B1 (ko) * 2010-09-30 2013-02-21 경북대학교 산학협력단 가돌리늄 착물을 함유하는 ｍｒｉ조영제
WO2015051362A1 (en) 2013-10-04 2015-04-09 Illinois Institute Of Technology Multifunctional chelators, complexes, and compositions thereof, and methods of using same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
EP3544964B1 (en) 2016-11-28 2020-06-17 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
JP7693317B2 (ja) 2017-05-05 2025-06-17 センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション 二官能性キレートの薬物動態増強及びその使用
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
MA49398A (fr) 2017-05-05 2020-04-22 Eric Steven Burak Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CN109810140B (zh) * 2017-11-22 2021-06-29 湖南科技大学 一种血红素配体模拟物及其合成方法
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation
CN110396122B (zh) * 2019-08-13 2020-10-27 牡丹江医学院 一种核磁共振造影剂、制备方法及其用于肿瘤诊断中的用途
KR102203368B1 (ko) * 2020-10-30 2021-01-14 경북대학교 산학협력단 신규한 화합물 및 이를 함유하는 mri 조영제
EP4059925A1 (en) * 2021-03-15 2022-09-21 Bayer Aktiengesellschaft New contrast agent for use in magnetic resonance imaging
US12565503B2 (en) * 2022-03-16 2026-03-03 Wenzhou Institute, University Of Chinese Academy Of Sciences Cyclic Gd (III) complex and preparation method and use thereof
CN115364684B (zh) * 2022-10-25 2023-01-03 天津大学 一种高通量荷正电纳滤膜及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132409A (en) * 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
US5049667A (en) * 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
US5006643A (en) * 1987-06-24 1991-04-09 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
JP2831073B2 (ja) * 1988-06-24 1998-12-02 ザ ダウ ケミカル カンパニー 大環状二官能キレート剤、その錯体及びそれらの抗体接合体
US5972307A (en) * 1989-10-23 1999-10-26 Nycomed Salutar, Inc. Dichelants
JPH04154729A (ja) * 1990-10-16 1992-05-27 Nippon Mejifuijitsukusu Kk 磁気共鳴造影剤
US5133956A (en) * 1991-05-30 1992-07-28 The Dow Chemical Company Radiolabeled metal-binding protein for the treatment of arthritis
JPH0656802A (ja) * 1992-03-27 1994-03-01 Nippon Mejifuijitsukusu Kk テトラアザシクロドデカン誘導体およびその用途
CA2092596A1 (en) * 1992-03-27 1993-09-28 Kan Kubomura Tetraazacyclododecane derivative and its use
FR2689739B1 (fr) * 1992-04-10 1994-07-08 Europ Sieges Automobiles Siege perfectionne a positions multiples.
US5310535A (en) * 1992-04-24 1994-05-10 The Dow Chemical Company Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
IT1265440B1 (it) * 1993-12-24 1996-11-22 Bracco Spa Formulazioni diagnostiche paramagnetiche e metodo d'uso delle stesse
DE69426811T2 (de) * 1993-12-30 2001-09-13 Guerbet, Villepinte Polyaminierte Liganden, Metallkomplexe, Verfahren zur Herstellung und diagnostische und therapeutische Verwendungen
US6693190B1 (en) * 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
DE19525924A1 (de) 1995-07-04 1997-01-09 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
ATE284714T1 (de) * 1996-10-21 2005-01-15 Quadrant Drug Delivery Ltd Plättchen-ersatzmittel und geeignetes konjugations-herstellungsverfahren
IT1291624B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
IT1293777B1 (it) * 1997-07-25 1999-03-10 Bracco Spa Processo per la preparazione di tetraazamacrocicli
IT1293778B1 (it) * 1997-07-25 1999-03-10 Bracco Spa 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
WO2001052900A2 (en) * 2000-01-21 2001-07-26 Mallinckrodt Inc. Novel orthogonally protected amino acid chelators for biomedical applications
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10135355C1 (de) * 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie

Also Published As

Publication number Publication date
KR20040030826A (ko) 2004-04-09
WO2003009874A1 (de) 2003-02-06
AU2002321236B2 (en) 2006-11-02
IL159290A0 (en) 2004-06-01
EP1409024A1 (de) 2004-04-21
BR0211273A (pt) 2004-08-03
CN1533286A (zh) 2004-09-29
CA2453106A1 (en) 2003-02-06
UY27390A1 (es) 2003-02-28
RU2004105261A (ru) 2005-07-10
MXPA04000401A (es) 2004-03-18
DE50212604D1 (de) 2008-09-18
JP2005504745A (ja) 2005-02-17
ATE403442T1 (de) 2008-08-15
PE20030322A1 (es) 2003-04-13
EP1409024B1 (de) 2008-08-06
PL366426A1 (en) 2005-01-24
US20030108486A1 (en) 2003-06-12
DE10135356C1 (de) 2003-04-17
US20070009442A1 (en) 2007-01-11
RU2305096C2 (ru) 2007-08-27
US7164016B2 (en) 2007-01-16
NO20040238L (no) 2004-01-19

Similar Documents

Publication Publication Date Title
AR036182A1 (es) Conjugados de biomoleculas y 1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion, su uso para la preparacion de medios de diagnostico por resonancia magnetica nuclear o radiodiagnostico o para la radioterapia, los agentes farmaceuticos que los contienen, y los conjuntos o kits para
AR015906A1 (es) Compuesto derivado de fenilo o piridilo, composicion farmaceutica que lo contiene y su uso en la preparacion de un medicamento
Szaciłowski et al. S-nitrosothiols: materials, reactivity and mechanisms
DE69122881D1 (de) Polyazamakrocyclische verbindungen für komplexierung metal-ionen
AR036213A1 (es) Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticas
PT85410A (de) Makrocyclische verbindungen
ATE121082T1 (de) Tri-azamakrozyklen und deren metall komplexe.
TR200002671T2 (tr) Bisiklo(2.2.1)Heptanlar ve ilgili bileşikler
TR199800602A2 (xx) Dithiolan t�revleri, haz�rlanmalar� ve terap�tik etkileri.
ES2052767T3 (es) Formadores de complejos, complejos y sales complejas, multinucleares y sustituidos, procedimientos para su preparacion, y agentes farmaceuticos que los contienen.
ES444523A1 (es) Un procedimiento para preparar nuevos derivados de benzo- triazol.
DE68928644D1 (de) Heterocyclische Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
Kalvoda et al. Polarographic analysis of solutions containing adsorbable complexes
ATE19251T1 (de) Hemmer der kollagenase der saeugetiere.
RU2008130887A (ru) Водорастворимое соединение бензоазепина и содержащая его фармацевтическая композиция
HUT51294A (en) Process for producing oligopeptides containing cyclic prolin-analogue amino acids and pharmaceutical compositions containing them as active components
EA200001165A1 (ru) Производные тетрагидрохинолина в качестве антагонистов глицина
ATE82505T1 (de) Absorptionsverbesserer.
DK640489A (da) C63-amidderivater af 34-de-(acetylglucosaminyl)-34-deoxy-teicoplaniner
KR900001673A (ko) N-치환 아미드 유도체
ERLICH et al. A spin label study of human erythrocyte carbonic anhydrases B and C
FI895937A0 (fi) Nya imidazolidinderivat, foerfaranden foer deras framstaellning samt laekemedel innehaollande dessa foereningar.
NO930068L (no) Nye kjemiske forbindelser
BG101942A (bg) Аналози на аргинина, притежаващи инхибираща активност върху nо-синтетазата
ATE127492T1 (de) Für photovernetzungsprozesse geeignete carbonylgruppenhaltige polyphosphazenderivate.

Legal Events

Date Code Title Description
FB Suspension of granting procedure